LEAP pre-CROI workshop 2026: recordings and presentations online
30 March 2026. Related: Conference reports, Antiretrovirals, CROI 33 (Retrovirus) 2026.
Simon Collins, HIV i-Base
Every year for the last ten years the LEAP research programme into long-acting and extended release (LA/ER) drugs for HIV, TB, hepatitis and other infections holds an investigator workshop just before CROI. [1]
Although these meetings of invited doctors, researchers, drug companies, donors, regulators and community advocates are closed, the presentations are posted open access shortly after the meeting.
The workshop included important opening plenaries on global access, including for people who use drugs and children and adolescents.
Recordings are hyperlinked from the programme below.
Welcome
Carl Dieffenbach, Senior Advisor to the Office of the Director, Fogarty International Center
Overview of workshop
Charles Flexner, Director LEAP, Johns Hopkins University
Plenary 1 – Access
Chair: Elaine Abrams, Columbia University
Global Access to Long-Acting Formulations for HIV: A Country Perspective
Francois Venter, Ezintsha
Considerations for the Development of Long-Acting Formulations for People Who Use Drugs
Sunil Solomon, Johns Hopkins University
Availability of LA Products for Children and Adolescents: When?
Moherndran Archary, University of Kwazulu-Natal
Global Access to Long-Acting Formulations for HIV: A Community Perspective
Imelda Mahaka, Pangea Zimbabwe AIDS Trust
Ronald Ssenyonga, Makerere University
Panel Moderator: Paul Domanico, Clinton Health Access Initiative
Focus Group 1 Report-Back
Best Practices for Managing HIV/HBV Coinfection in Those Starting or Switching to LA HIV Treatment
Chair: Chloe Thio, JHU
Co-Chair: Jordan Feld, UHN Research
Rapporteur: Monica Gandhi, UCSF
Plenary 2 – Products
Chair: Paul Domanico, Clinton Health Access Initiative
Preclinical Development of Long-Acting Anti-Infective Drugs and Formulations Supported by NIH
Roger Ptak, NIH
Long-Acting Injectable Agents as Tools to End TB: An Overview of Activities Supported by the Gates Medical Research Institute
Chris Vinnard, Gates Medical Research Institute
LONGEVITY Formulation Development for HCV and TB
David Thomas, Johns Hopkins University
All-in-one LA-TLD product for HIV treatment reached IND status
Rodney Ho, University of Washington
(Part 1 – Supporting Perspective)
Broadly Neutralizing Monoclonal Antibodies for HIV Treatment and Prevention: Why We Should Be Excited
Huub Gelderblom, HIV Vaccine Trials Network
(Part 2 – Counter-Perspective)
Broadly Neutralizing Monoclonal Antibodies for HIV Treatment and Prevention: Why We Should Be Cautious
Daniel Kuritzkes, Harvard University
Plenary 3 – Products
Chair: Kimberly Scarsi, University of Nebraska Medical Center
Current Status of the ViiV LA/ER Pipeline
Lionel Tan, ViiV Healthcare | Alex Rinehart, ViiV Healthcare
Current Status of the Merck LA/ER Pipeline
Luisa Stamm, Merck
Current Status of the Gilead LA/ER Pipeline
Moupali Das and Martin Rhee, Gilead Sciences
Current Status of the J&J Tuberculosis LA/ER Pipeline
Vivian Cox, Johnson & Johnson
Focus Group 2 Report-Back:
Best Practices for Managing HIV/HBV Coinfection in Those Starting or Switching to LA HIV Treatment
Chair: Brian Kearney, Exavir Therapeutics
Co-Chair: Paul Domanico, CHAI
Rapporteur: Keith Crawford, NIH
Industry Roundtable
ViiV, Merck, Gilead, J&J & Generic Representatives
Plenary 4 – Implementation
Chair: David Thomas, Johns Hopkins University
Focus Group 3 Report-Back:
Ending the HIV Epidemic—Is Lenacapavir the Answer?
Chair: Sinead Delany-Moretlwe, Wits RHI
Co-Chair: Angela Colbers, Radboud UMC
Rapporteur: Ethel Weld, JHU
What Is Implementation Science, and What Is Its Role in the NIH Research Portfolio?
Geri Donenberg, NIH
The New PEPFAR: Implications for LA Treatment and Prevention
Mike Reid, PEPFAR
Introduction to the LEAP User Preferences Core
José Bauermeister, University of Pennsylvania
Focus Group 4 Report-Back:
User Preferences Research—Specific Aims and Strategic Plans
Chair: José Bauermeister
Co-Chair: Rachel Bender Ignacio
Rapporteur: Karine Dubé
Reference
- Long-Acting/Extended Release (LA/ER) Antiretroviral Research Resource Program (LEAP) Investigator Meeting and Annual Workshop. 21 February 2026, Denver, Colorado.
https://longactinghiv.org/content/LEAP_Workshop_2026